Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CD38 | P28907 | 20/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 1/20 | 1.00 |
| ▸ | CYP2B6 | P20813 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25135859 | 1.00 | CD38 (1.00) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25136169 | 0.90 | CD38 (0.84) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25135802 | 0.90 | CD38 (0.84) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25135990 | 0.89 | CD38 (1.00) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25135803 | 0.89 | CD38 (1.00) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25136054 | 0.88 | CD38 (0.79) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL29182171 | 0.88 | CD38 (0.79) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL25136138 | 0.88 | CD38 (1.00) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL30040406 | 0.88 | CD38 (1.00) | CD38CYP2D6CYP2B6CYP2C19 | |
| SCHEMBL29182237 | 0.88 | CD38 (1.00) | CD38CYP2D6CYP2B6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO LTD (CN) | 2025-12-18 | — | — | US | disclosed |
| CN-115697985-B | CD38 inhibitors | 米托布里奇公司 | 2025-01-21 | — | — | CN | disclosed |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | Nanjing Immunophage Biotech Co., Ltd. (CN) | 2024-08-01 | — | — | US | disclosed |
| EP-4370512-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | Cytokinetics, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| CN-117813296-A | CD38 modulators and methods of use thereof | 赛特凯恩蒂克公司 | 2024-04-02 | — | — | CN | disclosed |
| CN-117715897-A | Compounds and their use as CD38 inhibitors | 南京艾美斐生物医药科技有限公司 | 2024-03-15 | — | — | CN | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. | 2023-04-20 | — | — | US | disclosed |
| CN-115697985-A | CD38 inhibitors | 米托布里奇公司 | 2023-02-03 | — | — | CN | disclosed |
| WO-2023288195-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CYTOKINETICS, INC. (US) | 2023-01-19 | — | — | WO | disclosed |
| WO-2022228496-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | NANJING IMMUNOPHAGE BIOTECH CO., LTD (CN) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230116972-A1 | CD38 MODULATORS AND METHODS OF USE THEREOF | CD38, CXCR4, FCGRT | CD38 1/4885CYP2D6 1605/4885CYP2B6 2184/4885 |
| US-20240254113-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, CD22, BCL6B | CD38 1/4885CYP2D6 2636/4885CYP2B6 3442/4885 |
| US-20250382283-A1 | COMPOUNDS AND THEIR USES AS CD38 INHIBITORS | CD38, FCGRT, CD22 | CD38 1/4885CYP2D6 2674/4885CYP2B6 3578/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.